Last reviewed · How we verify
NCT05167669: BM-RT-HIFU
Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU
NA trial testing HIFU-MRI guided in Bone Metastases in 10 participants. Completed in 1 January 2025.
31 December 2024
Quick facts
| Lead sponsor | Sana Boudabbous |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 1 October 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- HIFU-MRI guided
Conditions studied
- Bone Metastases — all drugs for Bone Metastases →
- Radiotherapy — all drugs for Radiotherapy →
- Pain — all drugs for Pain →
- MRI — all drugs for MRI →
Sponsor
Sana Boudabbous
Who can join
18 Months and older, any sex, with Bone Metastases or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Metastatic disease to the bone is a common cause of pain. External beam radiation therapy (EBRT) is the standard palliative treatment BUT pain improvement is observed in 60% to 80%. Combination of hyperthermia (HT) with radiation is strongly compelling. MR is providing accurate, tissue-independent thermometry for intra-procedural guidance of thermal therapy. In this project we aim to combine in an adjuvant setting mild hyperthermia to EBRT for sustained relief of pain in patients with symptomatic bone metastases.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunomodulation and targeted drug delivery with high intensity focused ultrasound (HIFU): Principles and mechanisms.
Ashar H, Ranjan A. · · 2023 · cited 41× · PMID 36965581 · DOI 10.1016/j.pharmthera.2023.108393 -
The Thermal Ablation with MRgFUS: From Physics to Oncological Applications.
Leporace M, Calabria FF, Siciliano R, Capalbo C, et al · · 2024 · cited 1× · PMID 39796667 · DOI 10.3390/cancers17010036
Verify or expand the search:
- PubMed search for NCT05167669
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bone Metastases
Currently open trials in the same condition.
- NCT06713941 — Management of Bone Metastases · active not recruiting
- NCT06392217 — clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases · recruiting
- NCT06065449 — A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation T · Phase 3 · recruiting
- NCT06487013 — Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases: A Pivotal Study · NA · recruiting
- NCT06189079 — Arterial Embolization for the Treatment of Bone Metastases: Prospective Observational Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05167669 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sana Boudabbous
- Last refreshed: 2 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05167669.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing